ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of data on its lead drug candidate CF-301 at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 21-24, 2018, in Madrid, Spain.

This entry was posted in Recent Development News: Q2 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »